Despite CETP Loss, Lilly Says Long-Term Strategy Is Starting To Bear Fruit
Drugs like baricitinib for rheumatoid arthritis, abemaciclib for breast cancer and solezumab for Alzheimer’s disease are among the six new molecular entities Lilly could file with regulators in the next 18 months.
You may also be interested in...
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.